ZIOPHARM Oncology Inc (NASDAQ:ZIOP) shares down by 5.96%, Pain Therapeutics, Inc (NASDAQ:PTIE)

Posted by sara Frank June 4, 2013 0 Comment 1385 views


ZIOPHARM Oncology Inc (NASDAQ:ZIOP): In Monday’s trading session, shares of ZIOPHARM Oncology Inc (NASDAQ:ZIOP) dipped by 5.96%. The opening price of the shares was $2.26 which reached an intraday high of $2.28 before dropping to $2.05 per share. In excess of 1.82M shares exchanged hands in the trading session on Monday. This number was higher than the average volume of 1.63M that was measured over 30-day period.

ZIOPHARM Oncology, Inc is a bio-pharma company. It concentrates on discovering and developing new and novel cancer therapies. The company applies its technologies for cancer research to develop numerous therapeutics for patients. ZIOP’s portfolio is made up of 5, clinical-stage product candidates and also multiple research-stage candidates. ZIOPHARM Oncology Inc (NASDAQ:ZIOP)’s clinical programs include IL-12 DNA, palifosfamide (ZIO-201), darinaparsin (ZIO-101) and indibulin (ZIO-301.  Palifosfamide is a deoxyribonucleic acid. It is a targeted cancer treatment which bypasses drug resistance that is mediated by aldehyde dehydrogenase. The latter is an enzyme that is associated with cancer stem-cells. It has a favorable toxicity-profile. The DNA therapeutic, IL-12 DNA, is delivered to the tumor in the patient and it expresses interleukin-12.

Pain Therapeutics, Inc (NASDAQ:PTIE): In Monday’s trading session, shares of Pain Therapeutics, Inc (NASDAQ:PTIE) dipped by 3.37%. The opening price of the shares was $2.67 which reached an intraday high of $2.68 before dropping to $2.58 per share. In excess of 0.708M shares exchanged hands in the trading session on Monday. This number was higher than the average volume of 0.607M that was measured over 30-day period.

Just last weekend, Pain Therapeutics, Inc (NASDAQ:PTIE) rose more than 25% after an announcement from Pfizer that it had closed a meeting with the U.S FDA and that it now has a clear-cut understanding of the measures that are required for the Remoxy approval to come through. Pfizer partners with Pain Therapeutics and also with Durect Corporation for developing the drug.

Austin, Texas-based PTIE is a 162M market-cap company. Its lead drug candidate Remoxy is an investigational drug. It has a controlled, release-formulation of oxycodone and is used in patients who suffer from moderate to severe chronic-pain. Its other product candidates are made up of abuse-resistant formulations of hydrocodone, hydromorphone and oxymorphone. The company also has a potential Alzheimer’s treatment.


About sara Frank

Sara Frank is our chief congressional correspondent, Sara has covered the presidential campaign, Congress and congressional campaigns. Prior to that, she covered the U.S. House. Sarahas also worked covering the House, Senate and campaign finance. Among the numerous honors she has received for his reporting, Sara is the recipient of an Emmy Award from The National Academy of Television Arts and Sciences. She was also nominated four times for a national Cable Ace Award.

View all post by sara Frank Visit author's website

Write Your Comment